anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Short term overall survival is, regardless of treatment allocation, expected to be very close to 100 %. The primary outcome is relapse rate. The power of the study depends on the number of observed relapses. If the relapse rate in the adjuvant carboplatin group, the reference group, is lower than the anticipated 9 %, we need to include more patients to the study. Based on all previous published material on adjuvant treatment in clinical stage I seminoma it is not possible to precisely estimate the correct relapse rate until the median follow-up is four years. Consequently, we will estimate the relapse rate in the reference group close to the end of accrual. If the estimated relapse rate, and thus the number of relapses, is lower than the anticipated we will increase the sample size to make sure that the study meets the minimum required number of relapses in the reference group. A possible inclusion of more study participants does not compromise the Type I error rate of the study.
Selection and breeding strategies to improve resistance to enteropathies are essential to reaching the sustainability of the rabbit production systems. However, disease heterogeneity (having only as major visible symptom diarrhoea) and low disease heritability are two barriers for the implementation of these strategies. Diarrhoea condition can affect rabbits at different life stages, starting from the suckling period, with large negative economic impacts. In this study, from a commercial population of suckling rabbits (derived from 133 litters) that experienced an outbreak of enteropathy, we first selected a few animals that died with severe symptoms of diarrhoea and characterized their microbiota, using 16S rRNA gene sequencing data. Clostridium genus was consistently present in all affected specimens. In addition, with the aim to identify genetic markers in the rabbit genome that could be used as selection tools, we performed genome-wide association studies for symptoms of diarrhoea in the same commercial rabbit population. These studies were also complemented with FST analyses between the same groups of rabbits. A total of 332 suckling rabbits (151 with severe symptoms of diarrhoea, 42 with mild symptoms and 129 without any symptoms till the weaning period), derived from 45 different litters (a subset of the 133 litters) were genotyped with the Affymetrix Axiom OrcunSNP Array. In both genomic approaches, rabbits within litters were paired to constitute two groups (susceptible and resistant, including the mildly affected in one or the other group) and run case and control genome-wide association analyses. Genomic heritability estimated in the designed experimental structure integrated in a commercial breeding scheme was 0.19-0.21 (s.e. 0.09-0.10). A total of eight genomic regions on rabbit chromosome 2 (OCU2), OCU3, OCU7, OCU12, OCU13, OCU16 and in an unassembled scaffold had significant single nucleotide polymorphisms (SNPs) and/or markers that trespassed the FST percentile distribution. Among these regions, three main peaks of SNPs were identified on OCU12, OCU13 and OCU16. The QTL region on OCU13 encompasses several genes that encode members of a family of immunoglobulin Fc receptors (FCER1G, FCRLA, FCRLB and FCGR2A) involved in the immune innate system, which might be important candidate genes for this pathogenic condition. The results obtained in this study demonstrated that resistance to an enteropathy occurring in suckling rabbits is in part genetically determined and can be dissected at the genomic level, providing DNA markers that could be used in breeding programmes to increase resistance to enteropathies in meat rabbits.
A method for the propagation of protozoa of the genus Theileria comprises the propagation of host cells containing the agamonts of the protozoa in association with a concurrent propagation of a tissue culture cell line not infectible with the protozoa, as a mixed culture carried out in an aqueous nutrient medium.  The tissue culture cell line may be the baby hamster kidney cell line BHK 21. The host cells may be blood leucocytes from an infected calf in the case of T. annulata or cells from the spleen or lymph nodes of an infected steer in the case of T. parva.  A typical culture medium comprises a mixture of borine serum, tryptose phosphate broth and Eagle's basal medium, preferably with an increased aminoacid and vitamin content.  The mixed culture may be sub-cultured by the monolayer culture technique. The mixed culture may be administered to cattle to render them immune to theileriasis.ALSO:A vaccine comprises living protozoa of the germs Theileria which have been propagated in host cells concurrently with a tissue culture cell line not infectible with the protozoa as a mixed culture in an aqueous nutrient medium.  The host cells may be blood leucocytes from an infected calf in the case of T. annulata or cells from the spleen of lymph nodes of an infected steer in the case of T. parva.  The tissue culture cell line may be baby hamster kidney cells BHK 21, which have been trypsinised. The culture medium contains the usual nutrients required in the p  propagation of animal cells, e.g. it may comprise a mixture of bovine serum, tryptose phosphate broth and Eagle's basal medium, preferably with an increased amino-acid and vitamin content. The mixed culture may be sub-cultured by the monolayer culture technique.  The protozoa is propagated by incubation of the mixed culture at 37-40 DEG C. and by successive transfers of the propagated mixed cell culture into a new culture medium, e.g. every third or fourth day.  The mixed tissue culture obtained by sub-culturing may be centrifuged and resuspended.  The suspension may be used as a vaccine for administration to cattle to render them immune to theileriasis.
1516442 Dispensing liquids by osmosis and gas pressure ALZA CORP 13 Aug 1976 [11 Sept 1975] 33834/76 Heading A5B [Also in Divisions B1 and Fl] A dispenser e.g. a buccal tablet 10, for dispensing an active agent composition 15 to a fluid-containing environment, comprises a wall 12 defining a compartment 13 which contains a mixture of the agent composition 15 and a gas-generating composition 16 which is activated by contact with the fluid. The wall 12 has a passage 14 for dispensing the agent and is made of a material that maintains its integrity during dispensing but is permeable to the fluid and impermeable to the agent 15 and gas-generating composition 16. At least one of the compositions 15, 16; or a further compound added to the mixture, is soluble in the fluid and, when in solution, creates an osmotic pressure gradient across the wall so that fluid is drawn into the compartment 13 to cause gas generation and therefore enhanced displacement of the agent from the dispenser 10. The mixture also may contain a surfactant to assist wetting and a foaming agent to aid dispensing. The dispenser may take the form of a parallelelepiped having two passages 14 (Figs. 2A, B, not shown) or a cartridge having a tapered passage 14 (Fig. 3, not shown), the latter type being suitable for dispensing a medicinal agent 15 into a body opening. Generally, however, the active agent 15 may be any composition that is dispensed to produce a useful result. The gasgenerating composition 16 is typically an effervescent couple such as an acid-base mixture, and several suitable chemicals are listed. Various suitable materials for all the components of the dispenser are described, as are processes for making the dispenser. Six examples are detailed. Typically, the ingredients may be mixed and compressed into a tablet which is then coated with the material to form the wall 12, the passage 14 being made by mechanical drilling.
Core-shell particles and methods of making and using thereof are described herein. The core is formed of or contains one or more hydrophobic materials or more hydrophobic materials. The shell is formed of or contains hyperbranched polyglycerol (HPG). The HPG coating can be modified to adjust the properties of the particles. Unmodified HPG coatings impart stealth properties to the particles which resist non-specific protein absorption and increase circulation in the blood. The hydroxyl groups on the HPG coating can be chemically modified to form functional groups that react with functional groups and adhere the particles to tissue, cells, or extracellular materials, such as proteins.
Background and Objectives: Left ventricular aneurysm (LVA) is associated with a decline in cardiac function, evidenced by a lower ejection fraction (EF), due to the reduction in the proportion of functional myocardium. The left ventricular end-diastolic volume (LVEDV), the left ventricular aneurysm volume (LVAV), and the LVAV/LVEDV ratio show a strong correlation with the EF. The aim of this study was to determine LVA characteristics post-myocardial infarction (basal vs. apical) and to evaluate the impact of aneurysm volume in diastole (LVAVd), aneurysm area in diastole (LVAAd), and their respective ratios with LVEDV and area (LVEDA) on the EF, in order to identify the most critical predictive factors for assessing and managing the negative impact of aneurysms on cardiac function. Materials and Methods: This observational study included post-infarction LVA patients at the "Dedinje" Cardiovascular Institute in Belgrade, Serbia, undergoing routine transthoracic echocardiography. Echocardiography assessed volumes (LVEDV, LVESV, LVAVd, LVAVs) and areas (LVAAd, LVAAs, LVEDA, LVESA) using the area-length method. The ratios (LVAVd/LVEDV, LVAVs/LVESV, LVAAd/LVEDA, LVAAs/LVESA) were derived from these measures. The left ventricular EF was calculated using Simpson's method. Results: Basal aneurysms showed a significantly smaller LVAVd (p = 0.016), LVAAd (p = 0.003), and LVAAs (p = 0.029) compared to apical aneurysms, indicating that basal aneurysms are smaller in size. However, there was no significant difference in the EF and overall LV volumes between the groups, although the basal aneurysm group had a slightly higher EF and end-diastolic volume, with a slightly lower end-systolic volume. Furthermore, when comparing the correlation between the EF and the LVAVd, the LVEDV, and the LVAVd/LVEDV ratio, the results indicate that the LVAVd had the greatest impact on the EF (-0.695), followed by the LVAVd/LVEDV ratio (-0.637), and the lowest correlation is between the EF and LVEDV. A similar relationship is observed when comparing the EF with the LVESV, the LVAVs, and the LVAVs/LVESV ratio. Conclusions: Basal aneurysms are significantly smaller than apical ones, yet EF and LV volumes remain similar between the groups, with the EF being slightly higher in the basal group. In cases of LVA, LVAVd shows the strongest negative correlation with the EF, indicating its significant impact on systolic function, followed by the LVAVd/LVEDV ratio, with the weakest correlation seen between the EF and LVEDV.
Potassium Chloride Extended-release Tablets, USP are a solid oral dosage form of potassium chloride. Each contains 600 mg or 750 mg of potassium chloride equivalent to 8 mEq or 10 mEq of potassium in a wax matrix tablet. This formulation is intended to provide an extended-release of potassium from the matrix to minimize the likelihood of producing high, localized concentrations of potassium within the gastrointestinal tract.

Potassium Chloride Extended-release Tablets are an electrolyte replenisher. The chemical name is potassium chloride, and the structural formula is KCl. Potassium chloride, USP is a white, granular powder or colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol.
Fludarabine Phosphate for Injection is a potent antineoplastic agent with potentially significant toxic side effects. Patients undergoing therapy should be closely observed for signs of hematologic and nonhematologic toxicity. Periodic assessment of peripheral blood counts is recommended to detect the development of anemia, neutropenia and thrombocytopenia.

In patients with impaired state of health, Fludarabine Phosphate for Injection should be given with caution and after careful risk/benefit consideration. This applies especially for patients with severe impairment of bone marrow function (thrombocytopenia, anemia, and/or granulocytopenia), immunodeficiency or with a history of opportunistic infection. Prophylactic treatment should be considered in patients at increased risk of developing opportunistic infections.

Fludarabine Phosphate for Injection may reduce the ability to drive or use machines, since fatigue, weakness, visual disturbances, confusion, agitation and seizures have been observed.
In some aspects, this disclosure relates to compositions and/or methods for identifying or diagnosing dental fractures. In some examples, a composition including a contrast agent is applied to a tooth, and then a diagnostic image of that tooth is obtained. The composition may include barium sulfate and/or radioactive iodine, which may be present in or throughout a dispersion medium facilitating application of the composition to a tooth. The barium sulfate may have a reduced particle size to facilitate dispersion within the medium, and therefore application to a tooth/ligament. The composition may include one or more oils, flavors, dyes, or other additives such as surfactants. The composition may be applied topically or via injection, such as injection into the adjacent periodontal ligament.
A mesenchymal stem cells cultured product and a method of preparing the same are provided. The preparation method of mesenchymal stem cells cultured product includes the following steps. A predetermined amount of mesenchymal stem cells is seeded in a flat culture device containing a first culture medium. When the mesenchymal stem cells proliferate to the target amount, the first culture medium is replaced with a second culture medium, and the second culture medium is removed after culturing for 18 to 30 hours. The target culture medium is added and incubated for 48 to 72 hours and repeat the collection of the target culture medium. The target culture medium is filtered and concentrated to obtain the mesenchymal stem cells cultured product.
The young and middle-aged hypertensive population is growing, but the optimal antihypertensive treatment strategy remains undefined. Young and middle-aged adults have poor adherence to antihypertensive medications and are prone to missed doses, and weekly formulations may be potentially advantageous. As a centrally acting antihypertensive agent, clonidine exerts sustained antihypertensive effects by agonizing alpha2-adrenoceptors. Clonidine controlled-release patches have the advantage of convenience in that they are administered once a week through a transdermal controlled-release technique to achieve a smooth and sustained action of clonidine. However, there is a lack of evidence from clinical trials on its efficacy and tolerability in the treatment of hypertension in young and middle-aged people. ECLIPSE trial is intended to explore the effect and patient tolerability of clonidine controlled-release patches (one patch per week for a total of 8 weeks) in the treatment of hypertension in young and middle-aged adults, compared with long-acting antihypertensive drug amlodipine. Clonidine patch was demonstrated ameliorating the early withdrawal symptoms during smoking cessation and recommended by American Cancer Society to help people quit smoking. Therefore, this trial is also intended to observe its effect on smoking cessation in young and middle-aged male smokers at the same time.
NEW MATERIAL:The piperazine derivative of formula I (A is aliphatic cyclic hydrocarbon group; R1, R2 and R3 are H or lower alkoxy) and its non-toxic salt. EXAMPLE:2-[ 4-(1-Admantylmethyl)piperazinyl ]-1-(3,4-dimethoxy-ph-enyl)ethanol dihydrochloride. USE:It has the activity to specifically dilate the peripheral vessel, especially the vertebral artery and increase the blood flow rate, and is useful as a cerebral circulation improver. PREPARATION:The compound of formula I can be prepared by reducing the compound of formula II. The reduction is carried out by the use of a metal hydrogen complex compound such as aluminum lithium hydride. An ether such as tetrahydrofuran, etc., is used as the reaction solvent, and the reaction temperature is preferably from 0 deg.C to the boiling point of the solvent.
Certain examples provide systems, methods, and apparatus for medical device management. An example method includes comparing a first identification of a first data set to a second identification of a second data set at a medical device. The example method includes, when the first identification does not match the second identification, triggering a download of the second data set to the medical device. The example method includes determining an operating state of the medical device. The example method includes, when the operating state indicates the medical device is idle, triggering activation of the second data set in place of the first data set at the medical device. The example method includes facilitating operation of the medical device according to the second data set.
INTRODUCTION: Serum levels of procalcitonin and C-reactive protein (CRP) have been used to predict anastomotic leakage after colorectal surgery, but information is scarce in advanced ovarian cancer (AOC) surgery with bowel resection. This study aimed to assess the predictive value of procalcitonin and CRP in detecting anastomotic leakage after AOC surgery with bowel resection. The study also aimed to determine the optimal postoperative reference values and the best day for evaluating these markers.
MATERIAL AND METHODS: This prospective, observational and multicentric trial included 92 patients with AOC undergoing debulking surgery with bowel resection between 2017 and 2020 in 10 reference hospitals in Spain. Procalcitonin and CRP levels were measured at baseline and on postoperative days 1-6. Receiver operating characteristic analysis was performed to evaluate the predictive value of procalcitonin and CRP at each postoperative day. Sensitivity, specificity, positive and negative predictive values were calculated.
RESULTS: Anastomotic leakage was detected in six patients (6.5%). Procalcitonin and CRP values were consistently higher in patients with anastomotic leakage at all postoperative days. The maximum area under the curve (AUC) for procalcitonin was observed at postoperative day 1 (AUC = 0.823) with a cutoff value of 3.8 ng/mL (83.3% sensitivity, 81.3% specificity). For CRP, the maximum AUC was found at postoperative day 3 (AUC = 0.833) with a cutoff level of 30.5 mg/dL (100% sensitivity, 80.4% specificity).
CONCLUSIONS: Procalcitonin and C-reactive protein are potential biomarkers for early detection of anastomotic leakage after ovarian cancer surgery with bowel resection. Further prospective studies with a larger sample size are needed to confirm these findings.
Patients receive regorafenib PO QD on days 1-21 of each cycle, venetoclax PO QD on days 1-21 of each cycle, and azacitidine IV over 10-40 minutes on days 1-7 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration during screening and on study as well as blood sample collection on study.
This group will participate in aerobic exercise intervention 3 times per week from enrollment to delivery. The aerobic training (AT) group will perform a continuous aerobic exercise of their choosing (e.g., treadmill, ellipticals, stairs, Zumba, or outside walking/jogging). Participants' ability to choose an aerobic activity that they are comfortable with and enjoy is intended to improve compliance.
PROBLEM TO BE SOLVED: To provide a starch material highly contg. dietary fibers and to provide food and drink, medicines, cosmetics, and industrial products contg. the same. SOLUTION: Starch contg. 30wt.% or higher amylose is subjected to a wet- heat treatment to give a starch material contg. 30wt.%, or higher dietary fibers. A mixture comprising 99-40wt.% high-amylose corn starch and/or its deriv. and 1-60wt.% starch contg. up to 30wt.% amylose is used as the starch contg. 30wt.% or higher amylose. The starch material highly contg. dietary fibers is incorporated into food and drink, medicines, cosmetics, and industrial products, thus giving products having physiologically active effects due to dietary fibers or products utilizing the excellent heat stability, fine particle size, and smooth touch of the material.
Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
OBJECTIVE: Spinal cord ischemia (SCI) after thoracic endovascular aortic repair (TEVAR) can cause permanent neurologic deficits and poor long-term survival. Targeted treatment of new SCI symptoms after TEVAR (rescue therapy [RT]) might improve/resolve neurologic symptoms but few data characterize the association of specific interventions with SCI outcomes. We evaluated the effectiveness of post-TEVAR RT at our tertiary aortic center.
METHODS: Our institutional TEVAR database was reviewed for SCI incidence and details of RT. This included cerebrospinal fluid drainage (CSFD), medical therapy, and optimization of spinal cord oxygen delivery. SCI outcomes were categorized at discharge as paralysis/paraparesis and temporary/permanent.
RESULTS: Nine hundred forty-three TEVAR procedures were performed in 869 patients from 2011 to 2020. Post-TEVAR SCI occurred in 7.8% (n = 74) with permanent paraplegia in 1.5%. Older patient age, chronic obstructive pulmonary disease, and previous abdominal aortic surgery were predictive of SCI. Half (n = 37) of SCI episodes resulted in only temporary paralysis/paraparesis. Rescue postoperative cerebrospinal fluid drains were implanted in 3.7% (n = 35) of procedures and was predicted by higher American Society of Anesthesiologists class, lower serum hemoglobin level, elevated international normalized ratio, bilateral iliac artery occlusion, nonelective procedures, and penetrating atherosclerotic ulcer/intramural hematoma indication. The most commonly used RTs were emergent placement of or increased drainage from an existing cerebrospinal fluid drain (87.8%), induced/permissive hypertension (77.0%), corticosteroid bolus (36.5%), and naloxone infusion (33.8%). Neurologic improvement occurred in 68.9% (n = 51/74). New/increased drainage was associated with improved SCI outcome.
CONCLUSIONS: Permanent paraplegia from post-TEVAR SCI is rare (1.5%). Older patients with comorbidities carry greater post-TEVAR SCI risk. SCI symptoms improved/resolved with CSFD and multimodal RT in 68.9% of patients, but no intervention was independently associated with improvement. TEVAR centers should have robust protocols for timely and safe CSFD placement to augment RT strategies for SCI.